-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target

Benzinga·10/27/2026 13:16:22
Listen to the news
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $35 price target.